MGC Pharmaceuticals continues its exponential growth, hitting 600 patient prescriptions across Australia and the United Kingdom.
This 600 patient milestone represents a 50% increase in prescription numbers in just two weeks since the 30th of September this year, amounting to an average of 19 prescriptions per day in October.
The prescriptions have primarily been two of MGC Pharma's proprietary products, CannEpil® and MXP100 (100mg/mL cannabidiol), which are both prescribed in Australia under the Special Access Scheme, as well as in the UK through specialised doctors under the Early Access to Medicines Scheme.
CannEpil® is the Company's high CBD, low THC formula (20:1) which is designed to treat drug-resistant epilepsy, whereas MXP100 is recommended for inflammatory disorders and for hepatoma patients.
The increased momentum of new prescriptions in Australia and the UK is a testament to the effectiveness of our phytocannabinoid medicines and growing recognition from, and use by, the medical community. Roby Zomer, Co-founder and Managing Director of MGC Pharma
Zomer went on to say that he " believe[s] that this is just the beginning of our market penetration and we will be able to sustain this attractive growth trajectory. With our unique EU-GMP production and key market distribution infrastructure now established, we can meet this increasing demand for our offering of phytocannabinoid derived medicines in our existing and future markets in both Europe and Australasia."
Disclaimer: Past performance is not an indicator of future performance.
Disclaimer: past performance is not an indicator of future performance
MGC's UK distribution partners are Grow Biotech PLC and IPS Specials, which provide the company access to over 5,500 pharmacies across the UK.
In Australia, MGC also works with Health House International, the first medical cannabis importer into Australia, who currently wholesales to pharmacists and researchers around the country, and Cannvalate, Australia's largest network of cannabis prescribers and dispensaries, who offer MGC Pharma access to over 1000 doctors and 600 pharmacies Australia-wide.
Alongside these distribution partnerships, MGC also works with Tetra Health and Cannabis Access Clinics, who both help to expedite the prescription process for Australians, by educating patients and prescribers about medicinal cannabis products.
A lack of practitioner and patient knowledge is considered one of the key barriers to prescription in Australia's relatively new medicinal marijuana landscape.
You can find out more about MGC Pharma on their company profile here.
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors